"Interferon beta-1a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An interferon beta-1 subtype that has a methionine at position 1, a cysteine at position 17, and is glycosylated at position 80. It functions as an ANTI-VIRAL AGENT and IMMUNOMODULATOR and is used to manage the symptoms of RELAPSING-REMITTING MULTIPLE SCLEROSIS.
| Descriptor ID |
D000068556
|
| MeSH Number(s) |
D12.644.276.374.440.890.275.500 D12.776.467.374.440.890.275.500 D23.529.374.440.890.275.500
|
| Concept/Terms |
Interferon beta-1a- Interferon beta-1a
- beta-1a, Interferon
- Interferon beta 1a
- 1a, Interferon beta
- beta 1a, Interferon
Avonex- Avonex
- Avonex Pen
- Pen, Avonex
|
Below are MeSH descriptors whose meaning is more general than "Interferon beta-1a".
Below are MeSH descriptors whose meaning is more specific than "Interferon beta-1a".
This graph shows the total number of publications written about "Interferon beta-1a" by people in this website by year, and whether "Interferon beta-1a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interferon beta-1a" by people in Profiles.
-
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-ß-1a Compared to Non-PEGylated IFN-ß-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
-
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
-
Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study. J Neurol Sci. 2017 Aug 15; 379:151-156.
-
Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26.
-
MS Forum/MS Over the Past 17 Years. Int MS J. 2011 Sep; 17(3):76-82.
-
Fingolimod for the treatment of relapsing multiple sclerosis. Expert Rev Neurother. 2011 Feb; 11(2):165-83.
-
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterol. 2009 Mar 20; 9:22.
-
Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84.
-
Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1. J Neuroimmunol. 2002 Aug; 129(1-2):205-15.